UK signs up to European rare diseases network The National Institute for Health and Care Research said membership of the European Rare Diseases Research Alliance will open “new pathways for UK researchers to participate in international clinical trials”.…
Everything you need to know about GLP-1s for weight loss From semaglutide to tirzepatide, this article collates the latest information on pharmacological weight-loss treatments, including evidence and best practice for their use.…
Minimum age set for puberty blockers trial To participate in the ‘PATHWAYS’ clinical trial, a modified protocol has ruled that birth-registered females must be aged between 11 and 16 years, and birth-registered males must be aged between 12 and 16 years.…
Why a research mindset matters in critical care pharmacy and beyond The Royal College of Pharmacy’s chief scientist reports back on a conversation with Cathrine McKenzie, professor of intensive care pharmacy at the University of Southampton, about the contribution that practising pharmacists can make to research.…
More than half of patients who stop weight-loss drugs restart within a year Researchers found that people taking newer medications, such as tirzepatide, were 41% less likely to discontinue than those taking older drugs, such as liraglutide.…
Health news round-up: elecoglipron, antibiotic resistant E. coli and low blood pressure risk in frailty The Pharmaceutical Journal’s weekly summary of the important developments in pharmacy and health news you may have missed.…
Drugs used for airway clearance in critically ill patients found to cause harm Researchers found that carbocisteine increased the risk of gastrointestinal bleeding, while hypertonic saline was associated with an increased risk of nebulisation-related harms in critically ill patients on mechanical ventilators.…
MS drug found to benefit patients with more advanced disease Researchers reported that ocrelizumab significantly reduced the risk of disability worsening in wheelchair-dependent patients.…
Virtual clinics could help improve access to adverse drug reaction services for children Three-quarters of adverse drug reactions assessed by a virtual clinic during the COVID-19 pandemic were related to antibiotics, study authors reported.…
Tezepelumab may reduce need for oral corticosteroids in severe asthma Study authors said their results “show the potential of tezepelumab to reduce maintenance oral corticosteroid use while maintaining asthma control and without compromising the efficacy outcomes”.…
